Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.4 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.